(Reuters) -Activist investor Glenview Capital said on Tuesday it had reduced its holdings in CVS Health following the insurer's "healthy" first-quarter results. CVS shares have generated a total return of 25% since it took a position last year, suggesting progress in the company's turnaround plan, the hedge fund said. Glenview previously owned nearly 12 million shares of CVS, according to its latest regulatory filing. It reduced its holdings by 3.75 million shares, just days after the healthcare conglomerate raised its annual forecast and beat Wall Street estimate for quarterly profit. CVS had been facing pressure from investors, including Glenview, to improve its operations and shareholder value after missing financial targets several times due to increased medical costs in its health insurance business. In October, CVS replaced CEO Karen Lynch with company veteran David Joyner and a month later added Glenview's top boss and three others to its board. Joyner has since laid out cost-cutting plans and reshuffled the top management to help the company navigate one of the most challenging periods in its six-decade history. Glenview said it has no plans for additional adjustments to its holdings with the company. "Our confidence in the near, medium and long-term outlook for CVS remains strong," the hedge fund said. Last week, CVS raised its 2025 profit forecast to $6 to $6.20 per share, from $5.75 to $6 projected previously. It also reported first-quarter profit above analysts' estimate on lower-than-expected medical costs. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Activist Glenview cuts stake in CVS after strong first-quarter earnings
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...